Highlights

  • BlinkLab established a 10-site US clinical network for its pivotal FDA 510(k) study of the Dx1 autism diagnostic platform.
  • The pivotal study is designed to enrol at least 528 children aged between two and eleven years across multiple US centres.
  • Earlier US pilot data involving 485 children reported 83.7% sensitivity and 84.7% specificity.
  • BlinkLab raised A$17.5 million to support its FDA study, European regulatory work and ADHD programme.
  • The company is also developing applications beyond autism, including ADHD, while pursuing regulatory and commercial opportunities in other markets.

Diagnosing autism can involve lengthy specialist waiting periods, repeated assessments and substantial costs for families and healthcare systems. BlinkLab (ASX:BB1) is developing a different approach built around technology already available in most households: the smartphone.

The Perth-headquartered medical technology company is developing a neurobehavioural assessment platform that uses a smartphone camera and microphone to measure responses in young children. Those responses are processed using computer vision and machine learning to support clinical assessment.

BlinkLab’s investment case increasingly centres on whether this technology can progress from promising clinical data into a regulatory-cleared diagnostic aid capable of being deployed at scale.

A major part of that process is its US clinical programme. During 2026, the company completed the network of ten clinical sites supporting its pivotal FDA 510(k) study and began enrolling participants, moving the platform further into formal clinical validation.

How BlinkLab’s Technology Works

BlinkLab was founded in 2017 by neuroscientists Dr Henk-Jan Boele and Dr Sebastiaan Koekkoek. The company’s technology has links to research conducted at Princeton University into autism, child development and neurological responses.

The company listed on the ASX in April 2024 after raising approximately A$7 million at 20 cents per share.

BlinkLab’s platform is designed to supplement conventional neurodevelopmental assessment with objective physiological measurements. Rather than relying exclusively on questionnaires, behavioural observations and clinician interpretation, the system measures involuntary neurological responses.

These include established neurometric tasks such as eyeblink conditioning, prepulse inhibition and startle habituation.

A smartphone camera records a child’s response frame by frame, while computer vision and machine-learning systems process the resulting data. The information is then uploaded to a secure cloud-based environment for analysis.

The aim is to create a relatively accessible and scalable clinical aid for neurodevelopmental conditions. Autism represents the company’s first major target, while Attention Deficit Hyperactivity Disorder (ADHD) and schizophrenia have also been identified as potential future applications.

The US Clinical Programme

One of BlinkLab’s most important operational developments in 2026 was the completion of its US clinical network for the pivotal FDA 510(k) study.

The University of Arkansas became the tenth site within the network, completing the multi-centre structure required for the planned validation programme.

The study is designed to assess both the usability and diagnostic accuracy of BlinkLab Dx1. It is expected to enrol a minimum of 528 children aged between two and eleven years.

The programme has been structured in two stages, beginning with a usability phase and followed by a double-blinded, multi-centre validation phase.

The company subsequently confirmed the enrolment of its first participant in late March 2026, formally moving the programme into patient testing.

Management has indicated an expected recruitment period of approximately eight months, with a 510(k) submission to the US Food and Drug Administration targeted for the second half of calendar 2026.

The regulatory programme follows an earlier US pilot study involving 485 children.

That study reported sensitivity of 83.7% and specificity of 84.7%, compared with the greater-than-65% benchmarks referenced by the company for both measures.

The pivotal study therefore represents the next major test of whether those earlier results can be reproduced across a larger, multi-site population under a formal regulatory framework.

Financial Position Reflects Clinical-Stage Status

BlinkLab remains a pre-commercial medical technology business, meaning its financial profile is primarily shaped by research, regulatory and development spending rather than established product sales.

For the half-year ended 31 December 2025, the company reported a net loss of approximately A$3.76 million.

Revenue was around A$160,600, reflecting the limited commercial contribution expected at this stage of development.

Cash and cash equivalents stood at approximately A$5.5 million at the end of December 2025. The company later received an approximately A$822,000 Research and Development (R&D) tax incentive refund.

Its funding position changed materially in June 2026 when BlinkLab completed a A$17.5 million placement at 65 cents per share.

The capital was raised to support the FDA registrational study, European regulatory activities and development of the company’s ADHD programme.

Following the raise, cash stood at approximately A$17.9 million as at 30 June 2026.

For a clinical-stage medtech, that funding provides greater capacity to progress key regulatory programmes without relying immediately on additional financing. However, meaningful product revenue remains dependent on regulatory clearance and subsequent commercial adoption.

Why the Autism Opportunity Matters

BlinkLab is targeting a healthcare problem where diagnostic capacity has struggled to keep pace with demand.

Autism diagnosis commonly involves specialist clinicians, structured observation, developmental histories and multiple assessments. In many healthcare systems, limited specialist availability can contribute to long waiting periods.

BlinkLab’s proposition is not necessarily to replace clinicians, but to provide an objective technology-assisted diagnostic aid that may help make assessments more scalable.

A smartphone-based system could also have advantages in accessibility. Unlike specialised imaging systems or laboratory equipment, smartphones are widely available and relatively easy to deploy across different clinical settings.

The commercial opportunity will ultimately depend on more than technical accuracy. BlinkLab would also need to demonstrate usability, clinical utility, acceptance among healthcare professionals and a pathway into reimbursement or healthcare funding systems.

Nevertheless, the size of the diagnostic bottleneck provides a clear rationale for developing technologies that can support earlier and more efficient assessment.

A Broader Neurodevelopmental Platform

BlinkLab’s longer-term strategy extends beyond autism.

The company is developing a second product candidate, Dx2, aimed at ADHD. It has also completed a European ADHD study involving approximately 375 children.

This creates the possibility that BlinkLab’s underlying neurobehavioural measurement platform could support multiple indications rather than functioning as a single-purpose autism product.

Schizophrenia has also been identified as a potential application.

That broader platform approach may be relevant to the company’s long-term economics. If the core technology can be adapted across multiple neurological or neurodevelopmental conditions, future applications could potentially share underlying infrastructure, software and data-processing capabilities.

However, each additional indication would still require appropriate clinical validation and potentially separate regulatory pathways.

International Expansion and Regulatory Pathways

The US represents BlinkLab’s most visible regulatory priority because FDA clearance could provide access to a large healthcare market.

The company is also pursuing European regulatory approval, including a CE Mark pathway.

Beyond traditional developed healthcare markets, BlinkLab has been selected for a government-funded nationwide autism screening programme in Morocco.

The programme relates to a market with approximately 600,000 births annually, giving BlinkLab an opportunity to explore how its technology could potentially be used in broader screening environments.

Another development supporting the company’s platform strategy was the grant of a US patent in June 2026 covering its remote neurobehavioural testing system.

The patent provides protection through 2041.

For a digital diagnostic business, intellectual property can be particularly important because the commercial value rests heavily on software, testing methodology, data processing and proprietary measurement techniques rather than physical manufacturing assets.

Key Risks Remain Substantial

BlinkLab’s progress does not remove the considerable risks associated with clinical-stage medical technology development.

Regulatory risk remains central.

The earlier pilot data reported sensitivity of 83.7% and specificity of 84.7%, but the pivotal study must demonstrate acceptable performance across a larger and more diverse multi-centre population.

Recruitment delays, lower-than-expected diagnostic performance, study-design issues or additional regulatory data requirements could extend development timelines.

Commercialisation also represents a separate challenge.

Even if regulatory clearance is achieved, adoption would depend on clinicians, healthcare systems and potentially payers accepting the technology as useful within existing diagnostic pathways.

Reimbursement is another consideration because regulatory clearance does not automatically guarantee that healthcare systems or insurers will pay for a diagnostic product.

BlinkLab also remains loss-making and pre-commercial.

The June 2026 capital raising improved the balance sheet, but further funding could eventually be required if clinical development, regulatory approval or commercial rollout takes longer or costs more than anticipated.

Future equity raisings could dilute existing shareholders.

Digital Diagnostics and the Industry Landscape

Interest in digital health and artificial intelligence-assisted diagnostics has increased as healthcare systems search for ways to improve access and reduce pressure on specialist services.

Neurodevelopmental assessment represents an area where digital tools may have particular relevance because conventional pathways can be time-consuming and dependent on limited specialist resources.

However, the same market opportunity is likely to attract competition.

BlinkLab may face competing digital diagnostic platforms, established clinical assessment methods and new technologies developed by larger healthcare organisations.

Its differentiation rests primarily on its use of objective neurological response measurements combined with smartphone delivery and machine-learning analysis.

The pivotal clinical programme will therefore be important not only for regulatory purposes, but also for demonstrating whether those characteristics translate into clinically useful differentiation.

What Matters From Here

The development of BlinkLab’s pivotal US study remains one of the most important indicators of future progress.

Recruitment across the ten clinical sites will show whether the company can execute the study within its planned timeframe and produce a sufficiently broad dataset for regulatory review.

The quality of the resulting clinical data will ultimately matter more than the speed of enrolment.

Sensitivity, specificity, usability and consistency across different study centres will all influence the regulatory case for Dx1.

The company’s financial position will also remain relevant. With approximately A$17.9 million in cash at 30 June 2026 following the capital raising, BlinkLab has increased its ability to fund its regulatory and development programmes.

Progress in Europe, the Morocco screening initiative and the ADHD programme could provide additional evidence of whether the underlying platform has applications beyond its first autism-focused product.

Conclusion

BlinkLab has progressed from early-stage neurobehavioural research toward a more structured clinical and regulatory programme.

The company has assembled a ten-site US clinical network, commenced participant enrolment and raised A$17.5 million to support the pivotal FDA study and other development activities.

Its earlier US pilot study involving 485 children reported 83.7% sensitivity and 84.7% specificity, providing a foundation for the larger validation programme.

At the same time, BlinkLab remains a pre-commercial and loss-making medtech whose future value depends substantially on clinical outcomes, regulatory clearance and eventual healthcare adoption.

The broader opportunity lies in whether its smartphone-based testing platform can become a scalable clinical tool not only for autism, but potentially for ADHD and other neurodevelopmental conditions.

For that longer-term thesis to develop, BlinkLab will need to demonstrate that encouraging early data can translate into reproducible multi-centre results, regulatory acceptance and practical use within healthcare systems.